Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-09-18
2007-09-18
Kumar, Shailendra (Department: 1621)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C549S450000, C549S453000, C514S467000
Reexamination Certificate
active
11111196
ABSTRACT:
The invention relates to compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds, wherein the compounds are of the following Formulas:or a pharmaceutically acceptable salt, ester or prodrug thereof, wherein the substituents are defined in the application. The invention further provides methods of treatment of inflammatory disorders by administering the compounds.
REFERENCES:
patent: 4029812 (1977-06-01), Wagner et al.
patent: 4076841 (1978-02-01), Wagner et al.
patent: 4078084 (1978-03-01), Wagner et al.
patent: 4752616 (1988-06-01), Hall et al.
patent: 4954514 (1990-09-01), Kita et al.
patent: 5155250 (1992-10-01), Parker et al.
patent: 5206247 (1993-04-01), Regnier et al.
patent: 5262439 (1993-11-01), Parthasarathy et al.
patent: 5608095 (1997-03-01), Parker et al.
patent: 5627205 (1997-05-01), Regnier et al.
patent: 5750351 (1998-05-01), Medford et al.
patent: 5773209 (1998-06-01), Medford et al.
patent: 5773231 (1998-06-01), Medford et al.
patent: 5807884 (1998-09-01), Medford et al.
patent: 5811449 (1998-09-01), Medford et al.
patent: 5846959 (1998-12-01), Medford et al.
patent: 6121319 (2000-09-01), Somers et al.
patent: 6147250 (2000-11-01), Somers
patent: 6548699 (2003-04-01), Somers
patent: 6602914 (2003-08-01), Meng
patent: 6617352 (2003-09-01), Somers
patent: 6828447 (2004-12-01), Meng
patent: 6852878 (2005-02-01), Meng et al.
patent: 6881860 (2005-04-01), Sikorski et al.
patent: 2002/0193446 (2002-12-01), Meng
patent: 2003/0064967 (2003-04-01), Luchoomun et al.
patent: 2004/0266879 (2004-12-01), Sikorski et al.
patent: 2005/0065121 (2005-03-01), Sikorski et al.
patent: 2005/0090487 (2005-04-01), Somers
patent: 2005/0171028 (2005-08-01), Meng et al.
patent: 0 348 203 (1989-12-01), None
patent: 0 405 788 (1991-01-01), None
patent: 0 621 255 (1994-10-01), None
patent: 0 763 527 (1997-03-01), None
patent: 2130975 (1972-11-01), None
patent: 2133024 (1972-11-01), None
patent: 2134810 (1972-12-01), None
patent: 2140769 (1973-01-01), None
patent: 2140771 (1973-01-01), None
patent: 2168137 (1973-08-01), None
patent: WO95/15760 (1995-06-01), None
patent: WO95/30415 (1995-11-01), None
patent: WO97/15546 (1997-05-01), None
patent: WO98/51289 (1998-11-01), None
patent: WO98/51662 (1998-11-01), None
patent: WO 00/26184 (2000-05-01), None
patent: WO 01/07057 (2001-09-01), None
Barnhart, J.W., et al., “Chapter 10: The Synthesis, metabolism, and biological activity of probucol and its analogs,”Pharmacochem. Libr., in Antilipidemic Drugs: Medicinal, Chemical, and Biochemical Aspects, Witiak et al., Eds., (Elsevier Science: Amsterdam, 1991), pp. 277-299.
Baron, J.L., et al., “The pathogenesis of adoptive murine autoimmune diabetes requires an interaction between a4-integrins and vascular cell adhesion molecule-1,”J. Clin. Invest., 93(4-6):1700-1708 (1994).
Burkly, L.C., et al., “Protection against adoptive transfer of autoimmune diabetes mediated through very late antigen-4 integrin,”Diabetes, 43:529-534 (1994).
Carew, T.E., et al., “Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: Evidene that antioxidantsin vivocan selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit,”Proc. Natl. Acad. Sci. U.S.A., 84:7725-7729 (Nov. 1987).
De Meglio, P., et al. “New derivatives of clofibrate and probucol. Preliminary studies on hypolipe-mic activity,”Farmaco, Ed. Sci., 40(11), 833-844 (1985). [In Italian; abstract provided in English:Chem Abstr. AN 1986:28675, DN 104:28675; & partial translation in English.
Elovaara, I., et al., “Adhesion Moleules in Multiple Sclerosis,”Arch. Neurol., 57:546-551 (2000).
Folkman, J. and Shing, Y., “Angiogenesis,”J. Biol. Chem., 267(16):10931-10934 (Jun. 5, 1992).
Foster, C.A., et al., “Novel Inhibitor of Endothelial Cell-Associated VCAM-1 Expression,”Skin Pharmacol., 9:149 (from 12thAnnual Meeting at pp. 141-168) (1996).
Haddad, J.J., et al., “Redox regulation of TNF-alpha biosynthesis: augmentation by irreversible inhibition of gamma-glutamylcysteine synthetase and the involvement of an IkappaB-alpha/NF-kappa.B-independent pathway in alveolar epithelial cells,”Cell Signal, 14(3):211-218 (Mar. 2002).
Kallmann, B.A., et al., “Cytokine-induced modulation of cellular adhesion to human cerebral endothelial cells is mediated by soluble vascular cell adhesion molecule-1,”Brain, 123:687-697 (2000).
Koch, A.E., et al., “Immunolocalization of endothelial and leukocyte adhesion molecules in human rheumatoid and osteoarthritic synovial tissues”,Lab. Investig., 64(3):313-320 (1991).
Koch, A.E., et al., “Angiogenesis mediated by soluble forms of E-selectin and vascular cell adhesion molecule-1,”Nature, 376(6540):517-519 (Aug. 10, 1995).
Kudlacz, E., et al., “Pulmonary eosinophilia in a murine model of allergic inflammation is attenuated by small molecule alpha4beta1 antagonists,”J. Pharmacol. Exp. Ther., 301(2):747-752 (May 2002).
Lee, S.J., et al., “Adhesion molecule expression and regulation on cells of the central nervous system,”J. Neuroimmunol., 98:77-88 (1998).
Marx, N., et al., “Peroxisome proliferator-activated receptors (PPARs) and their role in the vessel wall: possible mediators of cardiovascular risk?”J. Cardiovasc. Risk, 8(4):203-210 (Aug. 2001).
Meng, C.Q., et al., “Nitrobenzene compounds inhibit expression of VCAM-1,”Bioorganic&Medicinal Chemistry Letters, 11(14):1823-1827 (Jul. 23, 2001).
Meng, C.Q., et al., “Novel phenolic antioxidants as multifunctional inhibitors of inducible VCAM-1 expression for use in atherosclerosis,”Bioorganic&Medicinal Chemistry Letters, 12:2545-2548 (2002).
Meng, C.Q., “Probucol (Restenosis) Daiichi,”Curr. Opin. Cardiovasc. Pulm. Renal Invest. Drugs, 2(3):294-298 (2000).
Morales-Ducret, J., et al., “α4/β1 integrin (VLA-4) ligands in arthritis: vascular cell adhesion molecule-1 expression in synovium and on fibroblast-like synoviocytes”,J. Immunol., 149(4):1424-1431 (Aug. 15, 1992).
Nakao, H., et al., “An Inhibitor of VCAM-1 Expression and Its Implication as a Novel Treatment of Inflammatory Disease,”J. Atheroscler. Thromb., 4:149-155 (1998).
Nicolaou, K.C., et al., “Total Synthesis of Ionophore Antibiotic X-14547A,”J. Org. Chem., 50:1440-1456 (1985).
Oguchi, S., et al., “Monoclonal Antibody Against Vascular Cell Adhesion Molecule-1 Inhibits Neointimal Formation after Periadventitial Carotid Artery Injury in Genetically Hypercholesterolemic Mice,”Arterioscler. Thromb. Vasc. Biol., 20:1729-1736 (2000).
Ohkawara, Y., et al., “In situexpression of the cell adhesion molecules in bronchial tissues form asthmatics with air flow limitation:In vivoevidence of VCAM-1/VLA-4 interaction in selective eosinophil infiltration,”Am. J. Respir. Cell Mol. Biol., 12:4-12 (1995).
Pilewski, J.M., et al., “Cell Adhesion Molecules is Asthma: Homing, Activation, and Airway Remodeling,”Am. J. Respir. Cell. Mol. Biol., 12:1-3 (1995).
Rabb, H.A., et al., “The Role of the Leukocyte Adhesion Molecules VLA-4, LFA-1, and Mac-1 in Allergic Airway Responses in the Rat,”Am. J. Respir. Care. Med., 149:1186-1191 (1994).
Rival, Y., et al., “PPARalpha and PPARdelta activators inhibit cytokine-induced nuclear translocation of NF-kappaB and expression of VCAM-1 in EAhy926 endothelial cells,”Eur. J. Pharmacol., 435(2-3)143-151 (Jan. 25, 2002).
Schreiner, E.P., et al., “Inhibitors of vascular cell adhesion molecule-1 expression,”Expert Opin. Ther. Patents, 13(2):149-166 (2003).
Tardif, J.C., et al., “Effects of AGI-1067 and probucol after percutaneous coronary interventions,”Circulation, 107(4):552-558 (Feb. 4, 2003).
Yang, X.D., et al., “Inhibition of insulit
Meng Charles Q.
Weingarten M. David
AhteroGenics, Inc.
King & Spalding
Kumar Shailendra
LandOfFree
Phenolic antioxidants for the treatment of disorders... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Phenolic antioxidants for the treatment of disorders..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Phenolic antioxidants for the treatment of disorders... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3734219